Antitope Announces Composite Protein Research Agreement with Cambridge Antibody Technology Group PLC  (CATG)  
4/24/2007 4:00:50 PM

24th April 2007 Antitope Ltd., announced a research agreement with the Cambridge Antibody Technology (CAT) for the generation of novel biologics for the potential treatment of cancer. As part of the agreement, Antitope will apply its proprietary Composite ProteinTM and EpiScreenTM technologies with the aim of developing a therapeutic protein with a reduced risk of immunogenicity.